Smith & Nephew plc (NYSE:SNN) Receives Average Rating of “Buy” from Analysts

Shares of Smith & Nephew plc (NYSE:SNNGet Rating) have received a consensus recommendation of “Buy” from the eight research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $1,462.33.

Several equities research analysts have weighed in on SNN shares. JPMorgan Chase & Co. increased their target price on shares of Smith & Nephew from GBX 1,376 ($16.70) to GBX 1,442 ($17.50) in a report on Wednesday, March 2nd. Royal Bank of Canada began coverage on shares of Smith & Nephew in a report on Tuesday, March 15th. They issued an “outperform” rating on the stock. Redburn Partners upgraded shares of Smith & Nephew from a “sell” rating to a “neutral” rating in a report on Friday, March 4th. Barclays dropped their price objective on shares of Smith & Nephew from GBX 1,680 ($20.39) to GBX 1,650 ($20.03) in a report on Tuesday, May 31st. Finally, UBS Group raised their price objective on shares of Smith & Nephew from GBX 1,200 ($14.56) to GBX 1,295 ($15.72) in a report on Friday, April 29th.

Several institutional investors and hedge funds have recently made changes to their positions in SNN. FMR LLC boosted its holdings in shares of Smith & Nephew by 640.8% during the 1st quarter. FMR LLC now owns 1,341,034 shares of the medical equipment provider’s stock worth $53,788,000 after buying an additional 1,160,015 shares during the period. Lazard Asset Management LLC bought a new stake in shares of Smith & Nephew during the 4th quarter worth about $31,930,000. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Smith & Nephew by 691.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 803,232 shares of the medical equipment provider’s stock worth $25,623,000 after buying an additional 701,806 shares during the period. Soleus Capital Management L.P. bought a new stake in shares of Smith & Nephew during the 4th quarter worth about $20,537,000. Finally, JPMorgan Chase & Co. raised its stake in Smith & Nephew by 218.3% in the 1st quarter. JPMorgan Chase & Co. now owns 776,810 shares of the medical equipment provider’s stock worth $24,781,000 after purchasing an additional 532,763 shares in the last quarter. 26.03% of the stock is owned by institutional investors.

Shares of NYSE SNN opened at $27.71 on Friday. The company’s 50 day simple moving average is $31.48 and its 200 day simple moving average is $32.73. Smith & Nephew has a fifty-two week low of $27.39 and a fifty-two week high of $44.27. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.21 and a current ratio of 2.08.

Smith & Nephew Company Profile (Get Rating)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures.

See Also

Analyst Recommendations for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.